Hemostemix (CVE:HEM) Shares Cross Below 50 Day Moving Average – What’s Next?

Hemostemix Inc. (CVE:HEM) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$0.21 and traded as low as C$0.10. Hemostemix shares last traded at C$0.11, with a volume of 196,551 shares.

Hemostemix Stock Down 5.3 %

The stock has a fifty day simple moving average of C$0.20 and a two-hundred day simple moving average of C$0.13. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a market cap of C$13.12 million, a PE ratio of -2.62 and a beta of 0.20.

Insiders Place Their Bets

In other Hemostemix news, Director Peter Alan Lacey bought 200,000 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were acquired at an average cost of C$0.15 per share, for a total transaction of C$30,000.00. Corporate insiders own 10.43% of the company’s stock.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.